FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2066-2067 May 8, 2008 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The approval by the Food and Drug Administration of bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF),¹ sparked enormous excitement among oncologists. Bevacizumab, the first cancer therapy that acts by blocking angiogenesis, is the result of the successful translation of pioneering work by the late Judah Folkman and his colleagues, who proposed that vascularization is essential for the growth of clinically relevant invasive carcinomas. A recent study by Fischer and colleagues² indicates that a monoclonal antibody against another angiogenic protein, placental growth factor (PlGF), may also be a useful antiangiogenic therapy for cancer in humans.

Tumor cells . . . [Full Text of this Article]

Source Information

From Johns Hopkins University School of Medicine, Baltimore.

This article has been cited by other articles:

• Engels, K, du Bois, A, Harter, P, Fisseler-Eckhoff, A, Kommoss, F, Stauber, R, Kaufmann, M, Nekljudova, V, Loibl, S (2009). VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection. J. Clin. Pathol. 62: 448-454 [Abstract] [Full Text]